diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5527diaendo-5527Research ArticleСтатьиArticlesЭкспертный совет по применению нового ингибитора ДПП-4 ТРАЖЕНТА (линаглиптин) в лечении сахарного диабета 2 типаExpert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitusСахарный диабетредакция журналаDiabetes MellitusEditorial teamdia@endojournals.ru201215062012152№2 (2012)103104Copyright © Сахарный диабет р., 20122012Сахарный диабет р.Diabetes Mellitus E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5527

В Москве 11 апреля 2012 г. состоялость заседание экспертного совета по применению нового ингибитора дипептидилпептидазы-4 (ДПП-4) ТРАЖЕНТА (линаглиптин) в лечении сахарного диабета 2 типа (СД2). Планируется, что препарат уже осенью станет доступен для пациентов.

сахарный диабетингибиторы ДПП-4линаглиптинdiabetes mellitusDPP-4 inhibitorslinagliptinReferencesDeacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism. 2011 Jan;13(1):7-18.Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism. 2011 Jan;13(1):7-18.Инструкция по медицинскому применению препарата Янувия (ситаглиптин). Регистрационный номер: ЛРС-003200/07.Инструкция по медицинскому применению препарата Янувия (ситаглиптин). Регистрационный номер: ЛРС-003200/07.Инструкция по применению лекарственного препарата для медицинского применения Онглиза ® (саксаглиптин) Реги- страционный номер: ЛРС-008697/10.Инструкция по применению лекарственного препарата для медицинского применения Онглиза ® (саксаглиптин) Реги- страционный номер: ЛРС-008697/10.Инструкция по медицинскому применению препарата Галвус (вилдаглиптин) Регистрационный номер: ЛРС-008119/08.Инструкция по медицинскому применению препарата Галвус (вилдаглиптин) Регистрационный номер: ЛРС-008119/08.Инструкция по медицинскому применению лекарственного препарата Тражента. Регистрационное удостоверение: ЛП-001430 от 12.01.2012.Инструкция по медицинскому применению лекарственного препарата Тражента. Регистрационное удостоверение: ЛП-001430 от 12.01.2012.Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012 Jul;74(1):75-85.Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012 Jul;74(1):75-85.Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on Glycemic control and markers of ƒ-cell function in patients with inadequatelyc ontrolled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011 Mar;13(3):258-267.Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on Glycemic control and markers of ƒ-cell function in patients with inadequatelyc ontrolled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011 Mar;13(3):258-267.Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi K.A, Woerle HJ. Safety and efficacy of linagliptin as addon therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011 Jan;13(1):65-74.Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi K.A, Woerle HJ. Safety and efficacy of linagliptin as addon therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011 Jan;13(1):65-74.Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24 week randomized study. Diabet Med. 2011 Nov;28(11):1352-1361.Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24 week randomized study. Diabet Med. 2011 Nov;28(11):1352-1361.Lewin AJ, Arvay L, Liu D, Patel S, Woerle HJ. Safety and Efficacy of Linagliptin as Add-on Therapy to a Sulphonylurea in Inadequately Controlled Type 2 Diabetes. European Association for the Study of Diabetes 46th Annual Meeting, Stockholm, Sweden. 20-24 September 2010; Poster 821.Lewin AJ, Arvay L, Liu D, Patel S, Woerle HJ. Safety and Efficacy of Linagliptin as Add-on Therapy to a Sulphonylurea in Inadequately Controlled Type 2 Diabetes. European Association for the Study of Diabetes 46th Annual Meeting, Stockholm, Sweden. 20-24 September 2010; Poster 821.Schlosser A, Owens D, Taskinen MR, Prato S del, Gomis R, Patel S, Pivovarova A, Woerle HJ. Long-term safety and efficacy of the DPP-4 inhibitor linagliptin: data from a large 2-year study in subjects with type 2 diabetes mellitus. 47th Ann Mtg of the European Association for the Study of Diabetes (EASD), Lisbon, 12-16 Sep 2011. Diabetologia. 2011;54(1):S108. Abstr 242.Schlosser A, Owens D, Taskinen MR, Prato S del, Gomis R, Patel S, Pivovarova A, Woerle HJ. Long-term safety and efficacy of the DPP-4 inhibitor linagliptin: data from a large 2-year study in subjects with type 2 diabetes mellitus. 47th Ann Mtg of the European Association for the Study of Diabetes (EASD), Lisbon, 12-16 Sep 2011. Diabetologia. 2011;54(1):S108. Abstr 242.Rendell M, Chrysant SG, Emser A, Eynatten M von, Patel S, Trujillo A, Woerle HJ. Linagliptin effectively reduces blood glucose independent of age in patients with type 2 diabetes. ENDO 2011, 93rd Ann Mtg and Expo of the Endocrine Society, Boston, 4 - 7 Jun 2011. Endocr Rev. 2011;32(3). Abstr 3-497.Rendell M, Chrysant SG, Emser A, Eynatten M von, Patel S, Trujillo A, Woerle HJ. Linagliptin effectively reduces blood glucose independent of age in patients with type 2 diabetes. ENDO 2011, 93rd Ann Mtg and Expo of the Endocrine Society, Boston, 4 - 7 Jun 2011. Endocr Rev. 2011;32(3). Abstr 3-497.Patel S, Weber S, Emser A, Eynatten M von, Woerle HJ. Linagliptin improves glycaemic control independently of diabetes duration and insulin resistance in patients with type 2 diabetes. 47th Ann Mtg of the European Association for the Study of Diabetes (EASD), Lisbon, 12-16 Sep 2011. Diabetologia. 2011;54(1):S339. Abstr 832.Patel S, Weber S, Emser A, Eynatten M von, Woerle HJ. Linagliptin improves glycaemic control independently of diabetes duration and insulin resistance in patients with type 2 diabetes. 47th Ann Mtg of the European Association for the Study of Diabetes (EASD), Lisbon, 12-16 Sep 2011. Diabetologia. 2011;54(1):S339. Abstr 832.Gallwitz B, Uhlig-Laske B, Battacharaya S, Patel S, Woerle H-J. Linagliptin has Improved Safety and Similar Efficacy to Glimepiride over 2 Years in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin. American Diabetes Association, 71th Scientific Sessions, San Diego, CA, June 24-28, 2011; 39-LB.Gallwitz B, Uhlig-Laske B, Battacharaya S, Patel S, Woerle H-J. Linagliptin has Improved Safety and Similar Efficacy to Glimepiride over 2 Years in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin. American Diabetes Association, 71th Scientific Sessions, San Diego, CA, June 24-28, 2011; 39-LB.Barnett AH, Tahrani AA, Eynatten M von, Emser A, Patel S, Woerle HJ. The novel DPP-4 inhibitor linagliptin is associated with a very low risk of hypoglycemia: results from a large phase III program. 71st Sci Sess of the American Diabetes Association (ADA), San Diego, 24-28 Jun 2011. Diabetes. 2011;60(suppl 1):A623. Abstr 2346-PO.Barnett AH, Tahrani AA, Eynatten M von, Emser A, Patel S, Woerle HJ. The novel DPP-4 inhibitor linagliptin is associated with a very low risk of hypoglycemia: results from a large phase III program. 71st Sci Sess of the American Diabetes Association (ADA), San Diego, 24-28 Jun 2011. Diabetes. 2011;60(suppl 1):A623. Abstr 2346-PO.

The authors declare that there are no conflicts of interest present.